The oral therapy is aimed at adults with chronic spontaneous urticaria (CSU) who do not respond adequately to H1-antihistamines
The company said the move applies to all doses and reflects its commitment to making its medicines more affordable for patients
BRAFTOVI in combination with cetuximab and mFOLFOX6 had previously received accelerated approval in December 2024 based on objective response rate (ORR) results
Brivaracetam is the bioequivalent to Briviact Oral Solution, 10 mg/mL, of UCB
Nadda underlined that India’s policy framework is aligned with this transformation
In 2025, over 1 million patients accessed Lilly treatments through LillyDirect
This multi-year CDMO agreement involves significant, ongoing manufacturing for a global pharmaceutical major
Net sales reached CHF 1,327.8 million, up 2.6% year-on-year in Swiss francs, or 4.3% at constant exchange rates
The drug’s safety profile in LIBRETTO-432 aligned with previous selpercatinib studies, showing no unexpected concerns
The NDA filing is supported by results from the phase III evERA Breast Cancer study
Subscribe To Our Newsletter & Stay Updated
